Evidence map›Paper›PMID 30825974›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2019

1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.

Kruttika Bhat, Sara Duhachek-Muggy, Renuka Ramanathan, Mohammad Saki, Claudia Alli, Paul Medina, Robert Damoiseaux, Julian Whitelegge, William H McBride, Dörthe Schaue and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Radiation-induced tissue damage and response.The Journal of pathology · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kruttika BhatDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Sara Duhachek-MuggyDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Renuka RamanathanDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Mohammad SakiDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Claudia AlliDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Paul MedinaDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA.
Robert DamoiseauxMolecular Screening Shared Resource, University of California at Los Angeles, USA; Jonsson Comprehensive Cancer Center at UCLA, USA.
Julian WhiteleggeMolecular Screening Shared Resource, University of California at Los Angeles, USA; Pasarow Mass Spectrometry Laboratory, University of California at Los Angeles, USA.
William H McBrideDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA; Jonsson Comprehensive Cancer Center at UCLA, USA.
Dörthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA; Jonsson Comprehensive Cancer Center at UCLA, USA.
Erina VlashiDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA; Jonsson Comprehensive Cancer Center at UCLA, USA.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA; Jonsson Comprehensive Cancer Center at UCLA, USA. Electronic address: pajonk@ucla.edu.
University of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer CenterUniversity of Colorado Cancer Center · US

Funding

Sample Engineering CoreU19AI067773 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AMUNDSON, SALLY A. · 2005 to 2024
$105.4M
UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHUTE, JOHN P, MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Glioblastoma, Glioblastoma Stem Cells and RadiotherapyR01CA200234 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJONK, FRANK · 2016 to 2020
$1.8M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA200234NIAID NIH HHS U19 AI067769NIAID NIH HHS U19 AI067773
6 · The paper itself

Abstract

objectiveExposure to lethal doses of radiation has severe effects on normal tissues. Exposed individuals experience a plethora of symptoms in different organ systems including the gastrointestinal (GI) tract, summarized as Acute Radiation Syndrome (ARS). There are currently no approved drugs for mitigating GI-ARS. A recent high-throughput screen performed at the UCLA Center for Medical Countermeasures against Radiation identified compounds containing sulfonylpiperazine groups with radiation mitigation properties to the hematopoietic system and the gut. Among these 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (Compound #5) efficiently mitigated gastrointestinal ARS. However, the mechanism of action and target cells of this drug is still unknown. In this study we examined if Compound #5 affects gut-associated lymphoid tissue (GALT) with its subepithelial domes called Peyer's patches.

methodsC3H mice were irradiated with 0 or 12 Gy total body irradiation (TBI). A single dose of Compound #5 or solvent was administered subcutaneously 24 h later. 48 h after irradiation the mice were sacrificed, and the guts examined for changes in the number of visible Peyer's patches. In some experiments the mice received 4 daily injections of treatment and were sacrificed 96 h after TBI. For immune histochemistry gut tissues were fixed in formalin and embedded in paraffin blocks. Sections were stained with H&E, anti-Ki67 or a TUNEL assay to assess the number of regenerating crypts, mitotic and apoptotic indices. Cells isolated from Peyer's patches were subjected to immune profiling using flow cytometry.

resultsCompound #5 significantly increased the number of visible Peyer's patches when compared to its control in non-irradiated and irradiated mice. Additionally, assessment of total cells per Peyer's patch isolated from these mice demonstrated an overall increase in the total number of Peyer's patch cells per mouse in Compound #5-treated mice. In non-irradiated animals the number of CD11b

conclusionIn summary, our study provides evidence that Compound #5 leads to an influx of immune cells into GALT, thereby supporting crypt regeneration preferentially in the proximity of Peyer's patches.

Indexed as

AnimalsApoptosisFemaleIntestinal MucosaIntestine, SmallMiceMice, Inbred C3HMice, Inbred C57BLNitrobenzenesPeyer's PatchesPiperazinesRadiation InjuriesRadiation-Protective AgentsRandom AllocationRegenerationWhole-Body IrradiationNitrobenzenesphenylpiperazinePiperazinesRadiation-Protective AgentsGastrointestinal acute radiation syndromeIntestinal stem cellsPeyer's patchesRadiation mitigation

Identifiers

PMID30825974
PMCPMC6400303
OpenAlexW2906563532

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.